Skip to main content
Top of the Page

SOHO Society News

SOHO Annual Meeting

Registration is open for SOHO 2024 Annual Meeting! The twelfth annual meeting of the society, SOHO 2024, will be held as a hybrid event (in-person and virtual) from September 4-7, 2024 at the George R. Brown Convention Center in Houston, Texas. Advances in leukemia, lymphoma, myeloma, myeloproliferative neoplasms, myelodysplastic syndromes and related malignancies are highlighted during the official educational program.

The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. The primary purpose of the SOHO meetings are to exchange the latest information in the hematologic oncology field. SOHO is the only global society that focuses solely on blood tumors. Importantly, SOHO meetings include outstanding leaders, innovators and budding young investigators that interact to stimulate progress in this important field.

The 2024 meeting promises to be a dynamic and informative event. SOHO is the premier meeting that focuses specifically on new advances and practical clinical applications in the field of hematologic malignancies. The speakers are a multidisciplinary group of internationally recognized experts that represent the spectrum of these diseases.

This year, more than 3,800 physicians, nurses and related healthcare specialists to participated in the 3.5-day meeting in several unique educational formats including General Sessions, Meet-the-Professor Sessions, Plenary Lectures, Expert Sessions, Oral Abstract Presentations and other interactive and informal exchanges. Topics covered the latest advances in the pathophysiology and therapy of: leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, related malignancies and exciting developments in cellular therapy.

 

 


Latest Clinical News

Risk of Bleeding Events in Patients With CLL Receiving BTKis

The incidence of bleeding events in patients with CLL receiving BTKis is 26.6 per 100 patients per year, according to a study presented at the 2024 American Society of Clinical Oncology Annual Meeting.

Analysis Shows MPN Depend on JAK Mutation for Persistence

MPN depend on mutated JAK signaling, and targeting the mutations suppressed disease features and improved overall survival.

Pelabresib With Ruxolitinib in Myelofibrosis

Pelabresib plus ruxolitinib improved spleen and symptom responses in JAKi-naïve patients with myelofibrosis.

FDA Approves Imetelstat for Patients With Lower-Risk MDS With Transfusion-Dependent Anemia

The approval was based on efficacy and safety results of the randomized, placebo-controlled IMerge study.

Luspatercept Improves Anemia Metrics Across Myelofibrosis Cohorts

Treatment with luspatercept improved transfusion burden and anemia across four cohorts of patients with myelofibrosis.

The HemOnc Pulse Live Unanswered Questions in Aggressive Non-Hodgkin Lymphoma

An expert panel convened at the "HemOnc Pulse" Live meeting in Chicago explores unanswered questions in DLBCL management.

The HemOnc Pulse Live What Are the Unanswered Questions in ALL

The panel discussed ALL treatment, associated toxicities, and the possibility of a chemotherapy-free approach.

Low-Dose Azacitidine Plus Venetoclax Is Effective Maintenance for AML

Low-dose azacitidine plus venetoclax was a feasible maintenance regimen in AML after intensive or low-intensity induction.

What are the Controversies Surrounding MRD in Blood Cancers

Alan Skarbnik, MD, and Manni Mohyuddin, MBBS, discuss the concept of MRD in hematologic malignancies.

Member Spotlight

Guillermo Garcia-Manero, MD | SOHO President 2024

The Board of Directors and the Steering committee of the Society of Hematologic Oncology are pleased to announce that Dr. Guillermo Garcia-Manero (GGM) assumed the position of SOHO President on September 10, 2023. He will oversee the society during the 2023-2024 term and will Chair the SOHO 2024 annual meeting scheduled for September 4-7, 2024.

GGM has served on the SOHO Steering, Education and Scientific committees since the inception of the society in 2012. His efforts have focused on improving the outcomes and quality of life of patients with leukemia and, in particular, myelodysplastic syndromes. His work centers around the understanding of the pathophysiology of these disorders in order to develop new therapeutic interventions. He currently leads the largest MDS program in the world and directs the MDS/AML Moon Shot® program at UT MD Anderson Cancer Center (MDACC). This work has resulted in over 500 publications in the areas of biology, therapy and prognostication of these disorders, and development of multiple therapeutic clinical trials.

GGM is the Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research in the Department of Leukemia at MDACC. He also serves as the Chief of the Section of Myelodysplastic Syndromes and Vice Chairman of the Department of Leukemia. In addition, GGM serves as the Program Director of the Leukemia Fellowship Program at MDACC.

GGM was born in Spain and received his medical degree and training at the University of Zaragoza in Spain and at the Royal Free Hospital in London, UK. He completed his internship and residency in Internal Medicine at Thomas Jefferson University Hospital in Philadelphia, PA and his fellowship in Hematology and Medical Oncology at the Cardeza Foundation for Hematology Research, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, where he served as Chief Fellow. In 1999, he became Assistant Professor in the Department of Leukemia at MDACC where he continues to improve outcomes for patients diagnosed with MDS and leukemia.

Please join us in congratulating Dr. Garcia-Manero!

CLML Journal Content

BCT News

Back to Top